Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03830697
Other study ID # 2018-11-29
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 1, 2018
Est. completion date December 31, 2021

Study information

Verified date November 2018
Source Shaanxi Hospital of Traditional Chinese Medicine
Contact Su Tongsheng
Phone 15929562568
Email chinasuts@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The trial was completed by Shaanxi Provincial Hospital of Traditional Chinese Medicine and Northwest Women and Children's Hospital. Thirty-five patients with POR who underwent ART (Assisted Reproductive) treatment were observed in each center. Patients in the experimental group were given acupuncture treatment for 12 weeks prior to COH. If the patient has a good COH timing during acupuncture treatment, she will enter the COH cycle at any time. Patients in the control group waited for 12 weeks before COH. In this study, the COH regimen of the two groups of patients was the same, and the appropriate ovulation induction protocol was selected by the investigator according to the B-ultrasound and endocrine conditions of the patient's menstrual day 1-3. At the end of treatment, patients were observed for the number of eggs in the COH cycle, fertilization rate, cleavage rate, available embryo rate, high quality embryo rate, implantation rate, ovarian reserve function assessment, menstrual status and peri-menopausal symptoms.


Description:

1.Acupuncture intervention

1. test group Patients in the experimental group were given acupuncture treatment for 12 weeks prior to COH. If the patient has a good COH timing during acupuncture treatment, he or she will enter the COH cycle at any time.

The acupuncture intervention program of the test group is as follows:

Acupoint group 1: Baihui(DU20), Zhongwan(RN12), Tianshu (ST25)(bilateral), Guanyuan(RN4), uterus (bilateral)(EX-CA1), Dahe(KI12) (bilateral),Zusanli (ST36)(bilateral), Sanyinjiao(SP6) (bilateral), Taichong (LR3)(both sides) Acupoint group 2: Baihui(DU20),ShenShu(BL23)、ZhongLiao(BL33)、TaiXi(KI3) Operation: The two-point group was used alternately, with the group 1 as the initial treatment. The patient took the appropriate position (point group 1 was taken in the supine position, group 2 was taken in the prone position), and the local skin of the acupoint was routinely disinfected. Baihui, flat thorn 0.5-1.0 inch; Tai Chong, acupuncture 0.5-1.0 inch in the direction of Yongquan; Shenshu, Taixi, straight thorn 0.5-1.0 inch; ZhongLiao(BL33) , inward and downward oblique thorn 2.0-2.5 inch, It is required to puncture the hole in the second hole; the remaining hole is straight 1.0-1.5 inch. All the acupoints are evenly inserted and twisted (the Baihui acupoints only turn around). Each time the needle is kept for 20 minutes, once every other day, 3 times a week for a total of 12 weeks.

2. Control group Patients in the control group waited for 12 weeks before COH。

2.Standard IVF/ICSI Process

1. COH process(In this study, the COH regimen was the same in both groups, and the investigator chose the antagonist regimen based on the B-ultrasound and endocrine conditions on the 1-3 day of menstruation.) 1)Gn start time: Menstruation Day3 days, B-ultrasound and hormone levels (FSH/LH/E2/P/β-HCG) suggest that the ovary is in a basal state; 2)Gn starting dose: 75~300 IU; 3)Gn dose adjustment: 5 days after administration, according to ovarian response (B-ultrasound and E2 levels) Whole Gn dose, hMG (Hemeiqi) can be added if necessary; 1 ovarian response is monitored every 1~2 days thereafter (B-ultrasound and E2 level), adjust the amount of Gn accordingly。 4)When the antagonist is added: when the dominant follicle is ≥12mm, add antagonist (Eugly) 250ug/d to HCG day (including HCG day); 5)HCG trigger timing and dose: at least 3 follicles ≥ 18mm, given HCG4000~8000IUim.

2. Eggs taken 36 hours after intramuscular injection of HCG:

3. In vitro fertilization, embryo culture:In vitro fertilization was performed 4 to 6 hours after egg retrieval, and Day 3 embryos were scored according to the general standards of each center.The two embryos with the highest score were labeled as the embryos of the first embryo transfer. The remaining embryos are often Freeze on Day3, Day5 or Day6.

4. Embryo transfer and corpus luteum support:On Day 3, the patient maintained bladder filling and transplanted 2 of the best quality under the guidance of transabdominal B-ultrasound.Embryo; or on day 5, under the guidance of transabdominal B-ultrasound, transplant 1-2 blastocysts; continue to gestrinone 20mg Bid po supports the corpus luteum.

5. Pregnancy test: 1)Determination of blood βHCG levels 14 days after ET or Cryopreserved embryo transfer (CET) to determine biochemical pregnancy; 2)If determined to be pregnant, continue corpus luteum support。 3)35 days after ET, determine the clinical pregnancy by transvaginal B-ultrasound, record the number of gestational sacs, location, large Small, the presence or absence of fetal buds, the presence or absence of fetal heart, other abnormal conditions.


Recruitment information / eligibility

Status Recruiting
Enrollment 140
Est. completion date December 31, 2021
Est. primary completion date February 28, 2021
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria:

1. POR compliant diagnostic criteria

2. Intracytoplasmic sperm injection, ICSI)? Indication with IVF or intracytoplasmic sperm injection (ICSI).

3.18=age<40

Exclusion Criteria:

1. Repeated spontaneous abortion 2 or more patients (including biochemical pregnancy abortion.

2. Patients who have failed to undergo repeated implantation (at least 3 transplanted transplants, at least 3-6 high-quality embryos without clinical pregnancy);

3. uterine malformation (single uterus, double uterus, double uterus, untreated mediastinal uterus) and other effects affecting uterine cavity disease (adenomyosis, submucosal uterine fibroids, intrauterine adhesions and scar uterus) Patient;

4. Patients and their husbands with abnormal karyotypes (excluding chromosomal polymorphisms;

5. Untreated patients with hydrosalpinx;

6. (6)Patients with contraindications to ART and pregnancy, or those with a clear influence on pregnancy, such as hypertension, clinically symptomatic heart disease, diabetes, liver disease, kidney disease, severe anemia, history of venous thrombosis, History of pulmonary embolism or cerebrovascular events, history of malignant tumors;

7. Refusal to sign the informed consent form.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Acupuncture intervention
Patients in the experimental group were given acupuncture treatment for 12 weeks prior to COH. If the patient has a good COH timing during acupuncture treatment, he or she will enter the COH cycle at any time.The acupuncture intervention program of the test group is as follows:Acupoint group 1: Baihui(DU20), Zhongyu(RN12), Tianshu (ST25)(bilateral), Guanyuan(RN4), uterus (bilateral)(EX-CA1), Dahe(KI12) (bilateral),Zusanli (ST36)(bilateral), Sanyinjiao(SP6) (bilateral), Taichong (LR3)(both sides).

Locations

Country Name City State
China Shaanxi Hospital of Traditional Chinese Medicine Xi'an Shaanxi

Sponsors (2)

Lead Sponsor Collaborator
Shaanxi Hospital of Traditional Chinese Medicine NorthWest Women and Children Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The number of eggs obtained in the COH cycle. The number of eggs obtained in the controlled ovarian hyperstimulation cycle. After an average of 13 days in the COH cycle
Secondary Ovarian reserve function assessment Basal sinus follicle count AFC, AMH and basal hormone levels (package)Including FSH, LH and E2) 12 week
Secondary Chinese Medicine Symptoms Scoring Standard for Menstruation Menstrual situation:Mainly assess the menstrual cycle and menstrual flow. menstrual cycle is based on the results of the patient's own comparison.Divided into normal cycle, early menstruation (>7 days before menstruation) and delayed menstruation (>7 days after menstruation) 3class. According to the patient's own comparison results, the menstrual volume is divided into normal menstruation and less menstrual flow.Reduce, or the menstrual period is less than 2 days, or even a drop. It is generally believed that the amount of menstruation is less than 20ml for less menstruation.Class 2. 12 week
Secondary Self-RatingAnxietyScale Menstrual disorders, less menstrual flow, hot flashes, night sweats or cold, convulsions, forgetfulness, irritability Insomnia, secondary symptoms include dizziness, tinnitus, dull complexion, waist and knee pain, itchy skin, low libido. 12 week
See also
  Status Clinical Trial Phase
Completed NCT03433768 - Androgen Receptor mRNA Expression is Positively Associated With Live Birth in Women Undergoing IVF Independently of the Type of Ovarian Response N/A
Recruiting NCT05601193 - Ovarian PRP Injection in Women With POR N/A
Suspended NCT03021915 - Single Center, Prospective Controlled Pilot Study of the OvaPrime Procedure N/A
Completed NCT04013984 - Acupuncture for Treatment of Patients With Poor Ovarian Response N/A
Completed NCT03447184 - Long-term Endogenous Androgen Priming in Bologna Criteria Poor Responder Patients - A Pilot Study
Completed NCT01816321 - Corifollitropin Alfa Followed by Menotropin for Poor Ovarian Responders Trial Phase 3
Recruiting NCT04310293 - Novel Therapy for Poor Responders Management N/A
Completed NCT05703308 - Menstrual Blood Stem Cells in Poor Ovarian Responders Phase 3
Terminated NCT00878124 - How Dose Coenzyme Q10 Supplementation During Infertility Treatment Effects Pregnancy Outcome N/A
Not yet recruiting NCT06089395 - The Effect of Jiajian Guishen Granules on the Modulation of Ovarian Function in Patients With Poor Ovarian Response(POR) Early Phase 1
Completed NCT01732094 - Corifollitropin Alfa Followed by hpHMG in a Long GnRH Agonist Protocol for the Treatment of Poor Ovarian Responders Phase 2
Completed NCT01732068 - Treatment of Poor Ovarian Responders With Corifollitropin Alfa Followed by hpHMG in a Short GnRH Agonist Protocol Phase 2
Recruiting NCT04717752 - A Randomized Controlled Study of Different Trigger Modes of Antagonist Regimen in Patients With Low Ovarian Reserve N/A
Recruiting NCT04024722 - Improving in Vitro Fertilization in Women With Poor Ovarian Response N/A
Completed NCT03994614 - the Effect of Transcutaneous Electrical Acupoint Stimulation on the Quality of Oocyte on Poor Ovarian Response(POR) N/A
Recruiting NCT02801591 - Effect of Recombinant Human Growth Hormone Injection on the Clinical Outcome of POR in Patients Undergoing IVF/ET N/A
Recruiting NCT04273256 - Myo-inositol for the Management of Poor Ovarian Responders: A Prospective Randomized Controlled Trial Phase 2/Phase 3
Recruiting NCT02993588 - Impact of Melatonin on IVF/ICSI Outcomes in Prospective Poor Responders Phase 2/Phase 3
Terminated NCT02418572 - Testosterone TRANSdermal Gel for Poor Ovarian Responders Trial Phase 3